Cargando…

Characteristics of physicians receiving large payments from pharmaceutical companies and the accuracy of their disclosures in publications: an observational study

BACKGROUND: Financial relationships between physicians and industry are extensive and public reporting of industry payments to physicians is now occurring. Our objectives were to describe physician recipients of large total payments from these seven companies, and to examine discrepancies between th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Norris, Susan L, Holmer, Haley K, Ogden, Lauren A, Burda, Brittany U, Fu, Rongwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507829/ https://www.ncbi.nlm.nih.gov/pubmed/23013260 http://dx.doi.org/10.1186/1472-6939-13-24

Ejemplares similares

Conflict of Interest Policies for Organizations Producing a Large Number of Clinical Practice Guidelines
por: Norris, Susan L., et al.
Publicado: (2012)

Conflicts of Interest among Authors of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus
por: Norris, Susan L., et al.
Publicado: (2013)

Conflict of Interest Disclosures for Clinical Practice Guidelines in the National Guideline Clearinghouse
por: Norris, Susan L., et al.
Publicado: (2012)

Correction: Conflict of Interest Disclosures for Clinical Practice Guidelines in the National Guideline Clearinghouse
por: Norris, Susan L., et al.
Publicado: (2013)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

Conflict of Interest in Clinical Practice Guideline Development: A Systematic Review
por: Norris, Susan L., et al.
Publicado: (2011)

Quality of Clinical Practice Guidelines for Glycemic Control in Type 2 Diabetes Mellitus
por: Holmer, Haley K., et al.
Publicado: (2013)

Voluntary disclosures of payments from pharmaceutical companies to healthcare professionals in Germany: a descriptive study of disclosures in 2015 and 2016
por: Stoll, Marlene, et al.
Publicado: (2020)

Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK database, 2015 and 2016 cohorts
por: Mulinari, Shai, et al.
Publicado: (2018)

Physicians’ attitudes towards disclosure of payments from pharmaceutical companies in a nationwide voluntary transparency database: a cross-sectional survey
por: Stoll, Marlene, et al.
Publicado: (2022)

Correction to: Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
Publicado: (2023)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Error in Payments From Some Pharmaceutical Companies
Publicado: (2019)

US Nationwide Disclosure of Industry Payments and Public Trust in Physicians
por: Kanter, Genevieve P., et al.
Publicado: (2019)

Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada
por: Lexchin, Joel
Publicado: (2021)

Limitations of A Measurement Tool to Assess Systematic Reviews (AMSTAR) and suggestions for improvement
por: Burda, Brittany U., et al.
Publicado: (2016)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan
por: Murayama, Anju, et al.
Publicado: (2020)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Patient Organizations’ Funding from Pharmaceutical Companies: Is Disclosure Clear, Complete and Accessible to the Public? An Italian Survey
por: Colombo, Cinzia, et al.
Publicado: (2012)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review
por: Ozieranski, Piotr, et al.
Publicado: (2021)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Pharmaceutical Company and Device Manufacturer Payments to Gastroenterologists and Their Participation in Clinical Practice Guideline Panels
por: Nusrat, Salman, et al.
Publicado: (2018)

Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Contemporary Analysis of Inconsistencies Between Physician-reported Disclosures at the AAOS Annual Meeting and Industry-reported Financial Disclosures in the Open Payments Database
por: Bovonratwet, Patawut, et al.
Publicado: (2022)

Environmental and social disclosures dataset for Malaysian public listed companies
por: Rosman, Nor Syazwani, et al.
Publicado: (2023)

Comparing pharmaceutical company payments in the four UK countries: a cross-sectional and social network analysis
por: Rickard, Emily, et al.
Publicado: (2023)

Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
por: Fabbri, Alice, et al.
Publicado: (2018)

Tourism companies' risk exposures on text disclosure
por: Li, Jianping, et al.
Publicado: (2020)

Erratum: Correction of Ethics Statement: Discordance between Physician and the General Public Perceptions of Prognostic Disclosure to Children with Serious Illness: a Korean Nationwide Study
por: Kim, Min Sun, et al.
Publicado: (2019)

Buyouts of Indian Pharmaceutical Companies by Multinational Pharmaceutical Companies: An Issue of Concern
por: Sreedhar, D, et al.
Publicado: (2011)

Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment
por: Rhee, Taeho Greg, et al.
Publicado: (2020)

Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012–2016)
por: Ozieranski, Piotr, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k324m5n2oh62ucuoed5kaalgnt